Vesicor Therapeutics Appoints Michael Tolentino as CEO to Lead p53-Based Cancer Therapy Development
核心洞察
Vesicor Therapeutics (搜索), an early-stage biotechnology company developing p53-based cancer therapeutics using engineered microvesicles, has appointed Michael Tolentino, M.D., as its new Chief Executive Officer.
Tolentino brings over two decades of pharmaceutical experience, including contributions to anti-VEGF (搜索) therapies like Avastin and leadership roles at multiple biotech companies, including Promedior (搜索) which was acquired by Roche for $390 million.
The leadership transition comes as Vesicor prepares for IND-enabling studies targeting FDA regulatory submission in 2027 and a potential de-SPAC merger with Black Hawk Acquisition Corporation (搜索).
Vesicor Therapeutics (搜索), an early-stage biotechnology company focused on developing p53-based cancer therapeutics using engineered microvesicles, has appointed Michael Tolentino, M.D., as its new Chief Executive Officer. The leadership change positions the company for its next phase of development as it prepares for regulatory submissions and a potential public market entry.
Leadership Transition and Strategic Direction
Tolentino succeeds founder Luo Feng, Ph.D., who will transition to the role of Chief Scientific Officer as the company advances its pipeline and prepares for a potential de-SPAC merger with Black Hawk Acquisition Corporation (搜索). Vesicor is working toward IND-enabling studies and targeting a regulatory submission to the FDA in 2027.
"Dr. Tolentino is an exceptional leader whose biotech industry expertise, deep relationships across the contract research organization (CRO) and pharma ecosystems and has a proven track record of creating shareholder value is exactly what Vesicor needs in its next CEO," said Warren Hosseinion, M.D., Chairman of the Board at Vesicor Therapeutics (搜索). "We are honored to have Dr. Tolentino as our new CEO as we work to complete our proposed de-SPAC merger with Blackhawk Acquisition Corporation and seek to accelerate our IND-enabling studies and IND-submission to the FDA."
Extensive Industry Experience
Tolentino brings more than two decades of experience across drug discovery, preclinical and clinical development, and the broader pharmaceutical industry. His career includes key contributions to the development of anti-VEGF (搜索) therapies, including work on Avastin during his time at Harvard Medical School in collaboration with Genentech. He has also held leadership roles as founder and executive at multiple biotechnology companies, including Acuity Pharmaceuticals, which later merged to form OPKO Health (搜索).
Throughout his career, Tolentino has been involved in the development of novel therapeutics across ophthalmology, oncology, and RNA-based treatments. He also played a role in the development of Bevasiranib, one of the first RNA interference drugs to enter clinical trials for retinal diseases.
Track Record of Value Creation
Tolentino has been involved in founding and leading several successful biotech ventures. These include Promedior (搜索), which was acquired by Roche in 2018 for $390 million with additional contingent payments. He also co-founded Aviceda Therapeutics (搜索), where he invented AVD-104 and served in various leadership roles from 2018 until the company secured $207.5 million in Series C financing in 2025.
Currently, Tolentino serves as Co-founder, CEO and Chairman of Avdarna Therapeutics (搜索) since 2021, a company developing AI-generated proprietary protein/peptide therapeutics. He is also Co-founder and Chief Development Officer of Aikium (搜索), Inc., which has developed Yotta-ML, described as the world's first proprietary 10^24 protein/peptide sequence structured data-set trained drug discovery AI platform.
Vesicor's Technology Platform
Vesicor's core technology platform focuses on delivering cancer therapeutics, including p53 gene-based treatments, via engineered microvesicles designed to target tumor cells. The company has not yet initiated the FDA approval process for its lead candidate and currently has no approved products.
The leadership transition comes at a pivotal time as Vesicor prepares for potential public market entry through its planned SPAC merger and advances its preclinical development efforts. The company's focus on p53-based therapeutics represents a significant approach in cancer treatment, as p53 is a critical tumor suppressor gene involved in preventing cancer development.